Modern patient-facing article summarizing antioxidant/inflammation claims, cancer-use context, limitations, and risks/interactions.
Essiac Tea
Essiac Tea is reviewed here as a nutrition-related cancer support topic, with attention to how patients may use it alongside oncology care, symptom management, weight maintenance, metabolic health, and treatment tolerance. Cancer-focused context Essiac Tea is included in this database as a nutrition strategy that may come up in cancer care conversations, patient support planning, integrative oncology discussions, or alternative.
NCI PDQ review of Essiac/Flor-Essence history, preclinical studies, human data, adverse effects, and evidence assessment.
NCI nutrition care source for oncology context, including the need to maintain adequate nutrition and caution around cancer diets that lack evidence.
NCI overview explaining that cancer patients may use CAM to cope with treatment side effects, comfort themselves, or try to treat cancer, and that CAM should be discussed with the care team. Used to frame grounding as supportive rather than curative.
Patient-facing NCI summary of Essiac/Flor-Essence use, ingredients, studies, safety, and FDA status.
MSK About Herbs monograph summarizing proposed uses, conflicting lab findings, breast cancer observational data, adverse reactions, and herb-drug interactions.
Mouse model study of Flor-Essence exposure and mammary tumor development.
Systematic review finding lack of high-quality clinical trials and inconclusive preclinical/lab evidence.
Preclinical prostate cancer study reporting no marked antiproliferative effect in the in vitro and in vivo models tested, while paclitaxel positive control showed effects.
Comprehensive in vitro analysis reporting antioxidant/immunomodulatory findings, ovarian carcinoma cytotoxicity, CYP450 inhibition, and fibrinolysis inhibition.
Observational study in women with breast cancer; did not find improvement in health-related quality of life or mood states, though some users reported perceived benefits.
In vitro breast cancer cell paper reporting stimulation of human breast cancer cell growth by Essiac and Flor-Essence herbal tonics.
Animal/in vivo analysis reporting modest gastric protection but no significant hepatoprotective, hypoglycemic, or immunomodulatory properties.
In vitro/non-cellular study reporting hydroxyl/superoxide radical scavenging and DNA-protective activity.
Case report of a man with hormone-refractory prostate cancer whose PSA declined after Essiac use; attribution remains case-level evidence.
Rat mammary tumor study reporting Flor-Essence did not inhibit mammary tumor development and tumor incidence was higher in Flor-Essence groups.
In vitro study reporting decreased proliferation of LNCaP prostate cancer cells and dose-dependent effects on T-cell proliferation.
In vitro comparison of Essiac and Flor-Essence across human tumor cell lines.
Review of chemistry and biological activity of herbs used in Flor-Essence and Essiac.
Short TreatmentUpdate review noting compounds with antioxidant and cell-growth effects, no obvious toxicity in reviewed patients, and recommendation for clinical trials.
Canadian task-force review of Essiac history, evidence, patient reports, and research recommendations.
Historical oncology nursing article about Essiac and its use among cancer patients.
Proponent/historical page describing claimed Caisse mouse studies, formula ingredients, and clinical history.
Proponent page listing cancer types said to appear in Bracebridge case histories and later reports.
Archive-oriented Essiac lineage page presenting Caisse, formula history, and lineage figures.
Historical/proponent account of Rene Caisse, supporting physicians, clinic controversy, Brusch, and Resperin transfer.
Proponent page presenting archive/testimony/lab-study arguments against the claim that there is no evidence for Essiac.
NCI complementary/alternative medicine context for questionable cancer-treatment claims.